Takeda completes Shire acquisition

Takeda Pharmaceutical has completed its acquisition of Shire, 8 months after the deal was announced, according to a press release.

The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders, the release said.

“We are delighted that the acquisition was approved by an overwhelming majority of our shareholders at Takeda’s extraordinary general meeting on December 5, 2018. We are also pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organizations and the smooth receipt of regulatory clearances,” Takeda President and CEO Christophe Weber said in the release. “The execution of our integration begins today, and we are confident in our ability to execute a smooth integration under the leadership of our experienced and diverse Takeda executive team with a strong track record.”

Takeda Pharmaceutical has completed its acquisition of Shire, 8 months after the deal was announced, according to a press release.

The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders, the release said.

“We are delighted that the acquisition was approved by an overwhelming majority of our shareholders at Takeda’s extraordinary general meeting on December 5, 2018. We are also pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organizations and the smooth receipt of regulatory clearances,” Takeda President and CEO Christophe Weber said in the release. “The execution of our integration begins today, and we are confident in our ability to execute a smooth integration under the leadership of our experienced and diverse Takeda executive team with a strong track record.”